Valuation: Insmed Incorporated

Market Cap 21.18B 18.97B 17.5B 15.84B 29.61B 2,017B 30.09B 209B 83.3B 1,055B 79.48B 77.79B 3,343B P/E 2026 *
-60.5x
P/E 2027 * 129x
Enterprise Value 20.58B 18.43B 17B 15.39B 28.77B 1,959B 29.24B 203B 80.92B 1,025B 77.22B 75.57B 3,248B EV / Sales 2026 *
11.4x
EV / Sales 2027 * 6.89x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day+14.55%
1 week+16.86%
Current month-2.67%
1 month-3.93%
3 months+7.73%
6 months-17.73%
Current year-36.17%
1 week 92.62
Extreme 92.625
114.51
1 month 92.62
Extreme 92.625
116.43
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.92
Extreme 21.92
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 09/09/2012
Director of Finance/CFO 45 30/01/2020
Chief Tech/Sci/R&D Officer 62 18/12/2019
Director TitleAgeSince
Chairman 75 15/06/2009
Chairman 57 07/11/2018
Director/Board Member 72 28/05/2014
Date Insider Type Main position Quantity % Market Cap. Importance
09/09/26 Sell

Director

-25,000 0.0114%
17/08/26 Sell

Director

-5,000 0.0023%
10/08/26 Exercice

Chief Operating Officer

719,550 0.3320%
Change 5-day change 1-year change 3-year change Capi.($)
+14.97%+16.86%-33.46%+366.76% 21.18B
+0.34%-3.03%+37.45%+61.06% 64.14B
+0.98%+2.68%+12.25%+83.90% 55.53B
+1.75%+2.01%+13.30%+105.71% 53.03B
-1.51%-1.47%+25.89%+54.80% 45.99B
-0.77%-3.02%+17.74%+98.65% 42.45B
+0.86%+1.18%+227.32%+934.93% 40.45B
-0.26%-4.20%+10.86%+45.18% 32.25B
-2.07%+42.73%+103.77%+90.26% 34.47B
-2.72%-8.79%+22.58%-5.63% 24.23B
Average +1.05%+3.75%+43.77%+183.56% 41.37B
Weighted average by Cap. +0.56%+3.13%+45.18%+171.39%

Financials

2026 *2027 *
Net sales 1.81B 1.62B 1.49B 1.35B 2.53B 172B 2.57B 17.83B 7.11B 90.12B 6.79B 6.64B 285B 2.91B 2.61B 2.4B 2.18B 4.07B 277B 4.13B 28.68B 11.44B 145B 10.92B 10.69B 459B
Net income -342M -307M -283M -256M -479M -32.59B -486M -3.37B -1.35B -17.06B -1.28B -1.26B -54.03B 179M 161M 148M 134M 251M 17.08B 255M 1.77B 705M 8.94B 673M 659M 28.31B
Net Debt -603M -540M -498M -451M -843M -57.44B -857M -5.95B -2.37B -30.06B -2.26B -2.22B -95.22B -1.13B -1.02B -938M -849M -1.59B -108B -1.61B -11.19B -4.46B -56.56B -4.26B -4.17B -179B
Projected Income Statement - Annual - Insmed Incorporated
Logo Insmed Incorporated
Insmed Incorporated is a global biopharmaceutical company. It is advancing a diverse range of approved and mid- to late-stage investigational medicines and drug discovery. Its advanced programs are in pulmonary and inflammatory conditions, including a therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. Its pre-clinical research programs encompass a range of technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Its first commercial product, ARIKAYCE (amikacin liposome inhalation suspension), is used for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. Its pipeline includes clinical-stage programs, brensocatib, TPIP, and INS1201 and pre-clinical research programs. Its INS1148 is an investigational monoclonal antibody.
Employees
1,664
Date Price Change Volume
29/10/26 US$110.92 +14.37% 9,140,396
28/10/26 US$96.98 +2.13% 4,648,668
27/10/26 US$94.96 +1.75% 3,349,378
26/10/26 US$93.33 -0.06% 3,379,924
23/10/26 US$93.39 -1.76% 3,414,134
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Insmed Incorporated
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
24
Last Close Price
96.98USD
Average target price
196.14USD
Spread / Average Target
+102.24%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Insmed Incorporated
  1. Stock Market
  2. Stocks
  3. INSM Stock